[Ip-health] Council of Europe calls on measures to encourage the pharmaceutical industry to respond more effectively to public health needs

Patrick Durisch durisch at ladb.ch
Thu Oct 1 05:19:43 PDT 2015

Dear all,

The Parliamentary Assembly of the Council of Europe has massively voted in favour<http://www.assembly.coe.int/nw/xml/News/News-View-EN.asp?newsid=5794&lang=2&cat=8> of a report/resolution entitled "Public health and the interests of the pharmaceutical industry: how to guarantee the primacy of public health interests?" (118 in favour, 8 against, 7 abstentions).

The final resolution can be found here<http://assembly.coe.int/nw/xml/XRef/Xref-XML2HTML-en.asp?fileid=22154&lang=en>, and the explanatory memorandum by the Rapporteur here<http://assembly.coe.int/nw/xml/XRef/Xref-XML2HTML-en.asp?fileid=22030&lang=en>.

Among the calls on the Council of Europe's members states (47 countries) contained in the resolution:

  *   oblige companies to ensure absolute transparency regarding the real costs of R&D
  *   adopt a stricter marketing authorisation policy (criteria of added therapeutic value, "need clause", ...)
  *   mandatory publishing of the results of all clinical tests on new medicines
  *   recourse, where necessary, to mandatory licenses to ensure that medicines whose effectiveness has been established remain on the market
  *   excluding those with a conflict of interest from sensitive decision-making, absolute transparency regarding linked interests of experts working with health authorities, obligation on pharmaceutical companies to declare linked interests with all health sector players
  *   mandatory levy on promotional activities of the pharmaceutical industry and use it, inter alia, to finance a public fund to be used for the independent training of health-care professionals
  *   introduce strict regulations governing the movement from a position in the public sector to one in the private sector (and vice versa)
  *   increase funding of patients' associations from public funds
  *   prohibit any agreement which aims to delay, for no medical justification, the marketing of generic medicines
  *   impose dissuasive fines of a percentage of their turnover for any illegality carried out by drug companies
  *   set up a public fund to finance independent research geared to unmet health needs, including in the field of rare and paediatric diseases
  *   calls on the WHO to put forward alternatives to the current patent-based model for developing drugs

The debates can still be followed on the webcast<http://clients.dbee.com/coe/webcast/index.php?id=20150929-1&lang=en&ch=4> in French or English for those who are interested. There are also (provisional) verbatim records<http://assembly.coe.int/Documents/Records/2015/E/1509291000E.htm> if you prefer.

Best wishes

Patrick Durisch
Responsable Programme Santé - Health Programme Coordinator

Déclaration de Berne - Berne Declaration
Av. Charles-Dickens 4, CH - 1006 Lausanne
Tel. direct : +41 21 620 03 06 | e-mail : durisch at ladb.ch<mailto:durisch at ladb.ch>| ladb.ch<http://www.ladb.ch/>
facebook.com/DeclarationdeBerne<https://www.facebook.com/DeclarationdeBerne> | twitter.com/LaDeclaration<https://twitter.com/LaDeclaration>

Business mondial, responsabilité globale.
Signez sans tarder l'initiative pour des multinationales responsables ! www.ladb.ch/initiative<http://www.ladb.ch/initiative>

More information about the Ip-health mailing list